-
Mashup Score: 3Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024 | Cytokinetics, Inc. - 4 month(s) ago
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR 2024 taking place online and in person in London, UK from January 25-27, 2024. Title: Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM CMR Sub-study Presenter: Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University Date: January
Source: ir.cytokinetics.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0
Expanding Development Program to Assess Potential of Aficamten in Additional Patient Population to Inform Increased Utility of Cardiac Myosin Inhibition SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ACACIA-HCM (A ssessment C omparing A ficamten to Placebo on C ardiac Endpoints I n A dults with Non-Obstructive HCM), a Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy
Source: ir.cytokinetics.comCategories: Cardiologists, Latest HeadlinesTweet
RT @Cytokinetics: Today we announced that new data from FOREST-HCM will be presented at #CMR2024. #HCM Read more: https://t.co/veKT1ANvz6…